Aortic Stent Grafts Market

The global Aortic Stent Grafts Market is valued at USD 3.8 Billion in 2024 and is projected to reach a value of USD 5.9 Billion by 2035 at a CAGR (Compound Annual Growth Rate) of 5.7% between 2025 and 2035.

An aortic stent graft, also referred to as an endovascular stent graft (EVAR), is a medical device used to treat aneurysms. The procedure involves inserting an artificial stent graft via an artery in the groin, positioning it over the enlarged area. These stent grafts are commonly used in endovascular repair for both abdominal and thoracic aortic aneurysms.

Key Highlights

• In 2024, based on the Product Type, the Abdominal aortic stent graft category accounted for significant market share of 62.5%.
• In 2024, based on the End User, the Hospitals category holds the largest market share
• North America dominated the Aortic Stent Grafts market with largest market share of 38.9% in 2024
• Asia Pacific region is anticipated to grow at the highest CAGR during the forecast period

{{bar_graph}}

Product type Overview

The product type segment is divided into Abdominal Aortic Stent Graft, and Thoracic Aortic Stent Graft. The Abdominal aortic stent graft segment held the largest share of 62.5% in the Aortic Stent Grafts market.

The Aortic Stent Grafts market growth is attributed due to an increase in the geriatric population and the rise of abdominal aortic aneurysm. Abdominal aortic stent graft is more common in the lower abdominal part, and most of the cases of Abdominal aortic stent graft either occur at the infrarenal or juxta renal part of the lower abdomen. This segment is use for treating the abdominal aortic aneurysms by reinforcing a part of the aorta using a minimally invasive procedure. One unit of abdominal aortic stent graft refers to a main body (main body or trunk or aorto-iliac bifurcated components) with no extensions.

Thoracic vascular stent grafting is a new form of treatment in the vascular stent grafts industry showing promising results. The thoracic vascular stent grafts market growth is fostered by the FDA approval of the thoracic vascular stent grafts in 2005 for descending thoracic aortic aneurysm. For Instance, In May 2023, Terumo Aortic today announced that the US Food and Drug Administration (FDA) has granted approval of the Relay®Pro Thoracic Stent-Graft device for the treatment of dissection and transection in the United States. Relay®Pro delivers uncompromised clinical performance in the lowest commercially available profile and is indicated for all pathologies of the descending thoracic artery; aneurysm, penetrating atherosclerotic ulcers, transection and dissection. Relay®Pro offers unparalleled accuracy, proven efficacy and durability as well as the widest range of sizes, tapering and configurations on the market.

End User Overview

The end user segment is divided into hospitals, and ambulatory surgical centers. The hospitals segment held the largest market share in 2024 for Aortic Stent Grafts market.

The hospital segment is driven by the availability of advanced facilities and the continuous growth of healthcare infrastructure within hospitals. This segment is driven by increasing in numbers of hospitals around the world and government investments in improving healthcare facilities. In developing countries, Due to limited reimbursement policies and low disposable income, many individuals prefer hospital care as the most accessible option. This trend is expected to drive growth in this segment, particularly among low- and middle-income groups, in the coming years.

Regional Overview

In 2024, the North America captured largest revenue share of 38.9%.

North America Aortic Stent Grafts market is driven by technological improvements, rising aortic aneurysm cases, and robust financial incentives in the United States and Canada. Moreover, the growing adoption of aortic aneurysm stent grafts in the country will drive the demand for therapies that include these devices, creating a positive environment for market expansion of the North American Aortic Stent Grafts market. For Instance, In February 2021, Medtronic plc, the global leader in medical technology, has voluntarily issued a global recall of unused Medtronic Valiant Navion™ thoracic stent graft system and informed physicians to immediately cease use of the device until further notice.

U.S. Aortic Stent Grafts Market

The U.S. Aortic Stent Grafts market, valued at USD 540 Million in 2024 to USD 810 Million in 2035, is anticipated to grow at a CAGR of 5.2% from 2025 to 2035. The market is driven by high inclination for minimally invasive operations, existence of favorable reimbursement regulations, and rising prevalence of aortic aneurysm. Based on the Centers for Disease Control and Prevention (CDC), around 9,904 people died in the U.S in 2019 as an outcome of an aortic aneurysm or aortic dissection. Approximately 75 percent of individuals with abdominal aortic aneurysms had a history of smoking.

Asia Pacific Aortic Stent Grafts Market

The Asia Pacific Aortic Stent Grafts market is driven by geriatric population increasing rapidly more prone to chronic diseases, rising awareness, favorable government policies, increased healthcare expenditure and modernization in medical infrastructure essentially in developing nations like India, China and Japan. Additionally, the growing incidence of cardiovascular diseases and hypertension in the region is driving the demand for advanced treatment solutions. Additionally, improvements in healthcare infrastructure and increased awareness are further enhancing the regions growth prospects.

China Aortic Stent Grafts Market

The China Aortic Stent Grafts market, valued at USD 505 Million in 2035, is anticipated to grow at a CAGR of 5.6% from 2025 to 2035. The market is fueled by a fast-rising population size, an increase in the occurrence of aortic aneurysms, and a growing desire for less invasive operations. Additionally, the market is driven by include technological innovations leading to more effective and minimally invasive procedures, as well as the rising demand for quality medical care. In addition, favorable reimbursement policies and improvements in healthcare infrastructure are further contributing to the expansion of Aortic Stent Grafts market.

Europe Aortic Stent Grafts Market

The European Aortic Stent Grafts market is expected to account for a substantial share driven by the growing emphasis on early diagnosis and treatment, coupled with enhanced healthcare infrastructure, is driving market growth. Supportive reimbursement policies and rising healthcare spending in several European countries further contribute to the markets development.

Key Trends

• Technological Advancements: Continuous innovation in stent graft designs, materials, and delivery systems, making procedures more efficient and minimally invasive
• Aging Population: Rising cases of aortic aneurysms due to the aging global population, leading to higher demand for treatment options
• Minimally Invasive Procedures: Growing preference for minimally invasive techniques over traditional surgeries, resulting in faster recovery and reduced complication rates
• Improved Imaging and Diagnostics: Enhanced imaging technologies enabling earlier detection and more precise placement of stent grafts
• Regulatory Approvals and Reimbursement: Expansion of approval for new devices and favorable reimbursement policies boosting Aortic Stent Grafts market growth

{{dialog}}

{{dashboard_image}}

Track market trends LIVE & outsmart rivals with our Premium Data Intel Tool: Vantage Point

Market Dynamics

Increasing number of aortic aneurysm cases and rising prevalence of cardiovascular diseases

Increasing incidence of aortic aneurysms and the rising demand for minimally invasive procedures such as endovascular repairs. Furthermore, technological advancements and strategic activities by the manufacturers are expected to bring new aortic stent grafts market trends in the coming years. According to World Health Organization, most people in the WHO European Region consume far too much salt, and more than one in three adults aged 30–79 has hypertension, the medical term for high blood pressure. This matters because high salt intake raises blood pressure, which is a leading risk factor for cardiovascular diseases such as heart attacks and strokes. A new WHO/Europe report “Action on salt and hypertension” calls for an integrated approach to reduce salt intake and improve detection and control of hypertension to protect people’s health.

Growing Geriatric Populations

The growing geriatric population is a crucial driver of Aortic Stent Grafts market. The factors such as older individuals are more susceptible to aortic diseases, including aneurysms. According to the United Nations, the proportion of people aged 65 years and above is increasing at a faster rate than those below that age. This means that the percentage of the global population aged 65 and above is expected to rise from 10% in 2022 to 16% in 2050. It is projected that by 2050, the number of individuals aged 65 years or above across the world will be twice the number of children under age 5 and almost equivalent to the number of children under 12 years. Additionally, international migration is playing a significant role in shaping population trends in several countries around the world. In high-income countries, the contribution of international migration to population growth between 2000 and 2020 was higher than the balance of births over deaths.

High Cost of treatment

The high cost of aortic stent graft treatments is a major challenge, restricting access, particularly in developing regions or for patients lacking sufficient insurance coverage. The use of advanced materials like polyester fiber, ePTFE, and state-of-the-art balloon-expandable designs in manufacturing these stents contributes to their premium pricing.

Competitive Landscape

The Aortic Stent Grafts market is characterized by the presence of both established players and emerging companies, each strive for market share through product innovation, strategic partnerships, and geographic expansion. Industry giants like Cryolife Inc, Cook Medical Inc, Lombard Medical Inc, Becton, Dickinson and Company, Medtronic Inc, W.l. Gore & Associates, Cardinal Health, Bolton Medical, Endologix Inc, Microport Scientific Corporation Inc, JOTEC. These key players are investing heavily in research and development to enhance the performance of their stent grafts, improve patient outcomes, and reduce procedural risks. Additionally, they are expanding their market presence through acquisitions, partnerships, and collaborations, targeting both developed and emerging markets.

The key players in the global Aortic Stent Grafts market include - Cryolife Inc among others.

Recent Market Developments

W. L. GORE & ASSOCIATES, INC. RECEIVES U.S. FOOD & DRUG ADMINISTRATION (FDA) APPROVAL FOR LOWER PROFILE GORE® VIABAHN® VBX BALLOON EXPANDABLE ENDOPROSTHESIS, NOW 6 FR SHEATH COMPATIBLE

• In January 2024, As part of efforts to continuously improve medical solutions for patients with complex vascular disease, W. L. Gore & Associates, Inc. (Gore) announced recent FDA approval of a lower profile GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis (VBX Stent Graft). FDA approval of this innovation builds on a proven device which has become an important tool for treating complex vascular disease. In addition to offering the longest balloon expandable stent on the market with its 79 mm configuration, and the widest range of stent diameter adjustability, the VBX Stent Graft now also offers the most 6 Fr compatible configurations among balloon expandable stent grafts

Terumo India launches TREO® Abdominal Stent-graft system

• In August 2024, Terumo India, the Indian subsidiary of Terumo Corporation (TSE: 4543), a global leader in medical technology, today announced the launch of the TREO® Stent-Graft System, an advanced solution for Endovascular Aneurysm Repair (EVAR). Designed specifically for the treatment of infrarenal abdominal aortic aneurysms in adults with suitable anatomies, the TREO® Stent-Graft System stands out as the only EVAR graft featuring both suprarenal and infrarenal active fixation

Endologix Alto Abdominal Stent Graft System Introduced in Canada and Argentina

• In May 2021, Endologix LLC announced the first implant of its Alto abdominal stent graft in Canada after recent approval from Health Canada. Alto was also recently approved for commercial sale in Argentina

The global Aortic Stent Grafts market can be categorized as Product type, End User and Region.